Navigation Links
Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
Date:2/16/2009

HONG KONG, Feb. 16 /PRNewswire-Asia/ -- Today, Filligent, the Hong Kong- based biotech company, achieved CE certification for its revolutionary, anti- infective medical face mask, the BioMask. The BioMask is the first in a series of new products in Filligent's anti-microbial personal care range, BioFriend(TM), to be launched during 2009. By complying with the European Community's Medical Devices Directive 93/42/EEC, Filligent has met the stringent EU requirements for design, efficacy and safety of its innovative, germ-killing BioMask.

(Photo: http://www.xprn.com/sa/2009/02/16/200902161730.gif )

Due to its anti-microbial properties, the BioMask is a powerful weapon in the fight to contain and stop the spread of infectious respiratory diseases such as SARS and bird flu. During outbreaks of infectious disease, the ability to halt transmission, during early stages, could be critical in preventing the development of a full-blown pandemic.

The BioMask is based on an "intelligent filtration" technology and is fabricated from a scientifically designed and tested multilayer material which has in its internal structure a unique active layer which has highly targeted anti-microbial properties. This active layer aggressively detects, traps, and then rapidly kills pathogens, within minutes of contact.

This patented BioFriend(TM) textile layer CAPTURES pathogens by mimicking the sites on human cells to which they normally attach, and DESTROYS them by disrupting their surfaces (viruses) and cell walls (bacteria). Many viruses, including influenza viruses, are known to bind to a terminal sialic acid residue on the surface of the human cell membrane. The binding agent in the BioFriend(TM) textile mimics the binding action of sialic acid on influenza viruses.

Typical face masks (including standard surgical masks and N95s) do not kill airborne pathogens. They are based on a passive mechanical filtration design only. Thus, microbes on or inside the mask can stay alive for many hours, greatly increasing the likelihood of cross-contamination. When compared to the tight-fitting N95 face mask, the BioMask is far superior in terms of efficacy, comfort and breathability.

As part of the CE testing process, the BioMask was sprayed with live aerosolized Influenza A virus equivalent to 50 times the amount contained in a normal sneeze. (Bird flu is a strain of the Influenza A virus.) More than 99.9% of the viruses were killed after less than one minute. Similar tests were conducted on other key pathogens, with similar results. When the BioMask was tested in terms of all the major routes of exposure, oral and dermal, it showed no harmful effects on humans. The BioMask has been tested for dermal biocompatibility following internationally recognized standards set out in ISO10933: Biological Evaluation of Medical Devices. Tests were conducted to evaluate cytotoxicity to cells, skin irritation on contact, and skin sensitization after repeated contact. No cytotoxicity, irritation or incidence of sensitization was observed.

Filligent will unveil the BioMask to the world's leading infectious disease experts at the Asia Pacific Congress of Medical Virology, 26-28 February 2009, in Hong Kong. The commercial launch of the BioMask has been widely anticipated by health and medical professionals in Asia and Europe. With CE certification now in hand, Filligent expects widespread adoption of the mask by medical institutions and governments during 2009. The BioMask will also be available to consumers for direct retail purchase in leading drugstore chains in Hong Kong and China during the same period. We expect FDA classification later in the year.

About BioFriend

In 2008, Filligent developed a revolutionary technology, called BioFriend(TM), which kills viruses and bacteria on contact. BioFriend's molecular technology can be applied to substrates such as rayon and cotton textile fiber. BioFriend(TM) captures pathogens by mimicking the sites on human cells to which they normally attach, then, destroys them by disrupting their surfaces (viruses) and cell walls (bacteria). BioFriend(TM) kills germs including those that cause Influenza A (including bird flu), Herpes Simplex, rhinovirus, common colds, measles, pneumonia, SARS, tuberculosis, streptococcus, and MRSA. By targeting only the dangerous elements, BioFriend's intelligent filtration technology optimizes breathability and comfort. With its ability to kill a broad range of microbes, while applied to various substrates, BioFriend(TM) naturally lends itself to wide application across consumer products. BioFriend(TM) not only contains and protects against infection, but keeps items of everyday personal use, prone to bacterial and viral contamination, safe and clean.

About Filligent

Filligent is a Hong Kong biotech company that develops advanced and affordable "intelligent filtration" technologies designed to combat the transmission of diseases. Using biochemistry at the molecular level, its proprietary technologies seek out dangerous pathogens and chemicals and then kill or inactivate them before they enter the human body. Filligent is able to select and filter out dangerous agents from the air, water, and from off surfaces -- including the human skin. Filligent provides ordinary people with affordable and advanced protective devices against infectious or other diseases. Filligent gives people Health Choices. See http://www.filligent.com for more company information and full, independent test results.

    For more information on the BioMask, BioFriend(TM) or Filligent, contact:

     Ms. Joanne Ooi
     Chief Marketing Officer
     Filligent Limited
     Tel:   +852-2542-2400
     Email: joanne.ooi@filligent.com

'/>"/>
SOURCE Filligent
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
2. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
3. Yongye Biotechnology International to Expand its Network of Branded Stores
4. Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders
5. Yongye Biotechnology to Present at Roth Conference
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Volatile Economy / Fundraising Challenges Encourage Business Combinations Among Biotech Companies According to New Survey from CPA Firm Rothstein Kass
8. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
9. Energy, Biotechnology and Agribusiness Veterans Form SG Biofuels to Develop Jatropha as Low-Cost, Sustainable Oil
10. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
11. 23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... China , Feb. 4, 2016 Beike ... and various medical institutions attended a ceremony in late ... integrative, personalized cell therapy in 2016. ... "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" was ... Regional Cell Production Center, both subsidiaries of Beike Biotechnology ...
(Date:2/4/2016)... Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused ... announced that it will present at the 18 th ... February 8, 2016 at 10:00 a.m. EST in ... , DelMar,s president and CEO, will provide an update on ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... BEIJING , Feb. 4, 2016 Sinovac ... ), a leading provider of biopharmaceutical products in ... committee of its board of directors received on February ... 3, 2016, from a consortium comprised of PKU V-Ming ... Sinobioway Biomedicine Co., Ltd., CICC Qianhai Development ( ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
Breaking Biology News(10 mins):